/PRNewswire/ Sunrise, a healthtech company founded in 2015 in Belgium, has just closed a €3.25 million fundraising round. Led by Kurma Partners, this round.
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
- Extends Series A with additional EUR19 million led by Fund+
- Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials
- XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in the future
News provided by
Share this article
Share this article
GHENT, Belgium, March 16, 2021 /PRNewswire/ ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million. The financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ( Volition ) today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Walloon Region have awarded Volition an aggregate of approximately $13 million in non-dilutive funding including this most recent award. This additional funding consisted of a cash grant of $1.3 million and $2.7 million in loans. It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the Company s continued development, and this latest funding takes the total non-dilutive funding to-date from all sources to over $15 million, commented Cameron Reynolds, President and Chief Executive Officer of Volition. Mr. Reynolds added, We are delighted with the great progress we are making on s